| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9314 | 2011 |
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ... New England Journal of Medicine 364 (26), 2517-2526, 2011 | 5545 | 2011 |
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial A Hauschild, JJ Grob, LV Demidov, T Jouary, R Gutzmer, M Millward, ... The Lancet 380 (9839), 358-365, 2012 | 3592 | 2012 |
| Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015 | 3010 | 2015 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 2072 | 2014 |
| Efficacy and safety of vismodegib in advanced basal-cell carcinoma A Sekulic, MR Migden, AE Oro, L Dirix, KD Lewis, JD Hainsworth, ... New England Journal of Medicine 366 (23), 2171-2179, 2012 | 1684 | 2012 |
| Management of immune-related adverse events and kinetics of response with ipilimumab JS Weber, KC Kähler, A Hauschild Journal of Clinical Oncology 30 (21), 2691-2697, 2012 | 1610 | 2012 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1594 | 2015 |
| Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma GV Long, A Hauschild, M Santinami, V Atkinson, M Mandalà, ... New England Journal of Medicine 377 (19), 1813-1823, 2017 | 1587 | 2017 |
| Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ... New England Journal of Medicine 375 (19), 1845-1855, 2016 | 1491 | 2016 |
| Melanoma D Schadendorf, ACJ Van Akkooi, C Berking, KG Griewank, R Gutzmer, ... The Lancet 392 (10151), 971-984, 2018 | 1442 | 2018 |
| PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma MR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ... New England Journal of Medicine 379 (4), 341-351, 2018 | 1389 | 2018 |
| Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ... New England Journal of Medicine 381 (7), 626-636, 2019 | 1289 | 2019 |
| Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ... The lancet oncology 15 (3), 323-332, 2014 | 1226 | 2014 |
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial GV Long, U Trefzer, MA Davies, RF Kefford, PA Ascierto, PB Chapman, ... The lancet oncology 13 (11), 1087-1095, 2012 | 1040 | 2012 |
| Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ... Journal of clinical oncology 31 (5), 616-622, 2013 | 912 | 2013 |
| Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial AMM Eggermont, S Suciu, M Santinami, A Testori, WHJ Kruit, J Marsden, ... The Lancet 372 (9633), 117-126, 2008 | 779 | 2008 |
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study PA Ascierto, D Schadendorf, C Berking, SS Agarwala, CML van Herpen, ... The lancet oncology 14 (3), 249-256, 2013 | 770 | 2013 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639, 2017 | 763 | 2017 |
| Systematic review of medical treatment in melanoma: current status and future prospects C Garbe, TK Eigentler, U Keilholz, A Hauschild, JM Kirkwood The oncologist 16 (1), 5-24, 2011 | 759 | 2011 |
Dirk SchadendorfProfessor für Dermatologie, University Hospital Essen; University of Duisburg-Essen確認したメール アドレス: uk-essen.de